Translational Technologies for Ameliorating Brain Injury
改善脑损伤的转化技术
基本信息
- 批准号:10224681
- 负责人:
- 金额:$ 52.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-16 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal ModelAnti-Inflammatory AgentsAntiinflammatory EffectAreaArousalAstrocytesAttenuatedBehavioralBiodistributionBiological MarkersBrainBrain InjuriesBrain regionCardiopulmonary ResuscitationChronicClinical ResearchCognitiveComaCysteineDendrimersElectroencephalographyElectrophysiology (science)EntropyFemaleFrequenciesFutureGenderGoalsHalf-LifeHeart ArrestHippocampus (Brain)Hypothalamic structureInflammationInflammatory ResponseInjuryIntranasal AdministrationInvestigationIschemiaLeadLearningLong-Term EffectsMeasuresMediatingMemoryMicrogliaModelingMonitorNervous System TraumaNeurologicNeurological outcomeNeuropeptidesOutcomeOxidative StressPathway interactionsPatient-Focused OutcomesPatientsPatternPerfusionPropertyRattusRecoveryResearchResuscitationRodent ModelSignal TransductionSiteSleepStructureTechnologyTestingTherapeuticTherapeutic EffectWakefulnessWorkattenuationbasebehavior testbehavioral outcomeclinical applicationclinical translationclinically translatablecombinatorialdepressive symptomsexcitotoxicityexperimental studyglial activationimprovedimproved outcomeinflammatory markermalenanotherapynatural hypothermianeurobehaviorneurobehavioralneuroinflammationneuron apoptosisneurophysiologyneuroprotectionnovelorexin Aoxidative damageresponsetargeted deliverytargeted treatmenttranslational approachuptake
项目摘要
Abstract
Cardiac arrest (CA) has devastating consequences to survival and, even after successful resuscitation brain
injury can be quite severe. The broad goal of our research is to develop translational, therapeutic technologies
for mitigating brain injury from global ischemia following CA. One prevailing solution is therapeutic hypothermia
(TH). While TH has been shown to improve outcome, it does not promote arousal or reduce neuro-
inflammation. We now propose a novel and potentially translational delivery approach to promote arousal by
intranasal delivery of ORXA. In addition, we also focus on examining the intrinsic bio-distribution and anti-
inflammatory properties of dendrimers in a chronic long-term survival after CA. We propose discovery
experiments that, we hope to show, will lead to clinically translatable solutions.
This proposal is founded on exciting preliminary results. We have discovered an approach to targeting the
orexinergic pathway through the delivery of Orexin-A (ORXA). This idea is supported by our preliminary studies
that first showed that intra-cerebral ventricle (ICV) ORXA treatment reduces inflammation, and in addition, rapidly
enhances arousal. This idea is further validated by our novel quantitative EEG (qEEG) monitoring
technology. We have observed brain injury and poor outcome due to neuro-inflammation post-CA brain injury.
In our preliminary studies, we found that uptake of dendrimers, specifically Dendrimer- N-acetyl cysteine (D-
NAC), occurs at injured brain regions. We have shown that dendrimers serve as a targeted therapeutic
technology for neuro-inflammation by attenuating neuro-inflammation, oxidative stress and
excitotoxicity. Further, we extend our work to long term observations and set up gender-specific models.
For the proposed investigations, we will utilize extensively researched and validated rodent model of CA and
resuscitation, propose both acute and chronic experimentation in male and female subjects and carry out the
monitoring of systemic perfusion, electrophysiological (qEEG) monitoring, comprehensive behavioral
examination, and histopathological analysis.
Our overarching hypothesis is that intranasal ORXA will initiate brain arousal effects and early anti-inflammatory
response, while dendrimer nanotherapy, D-NAC, will reduce chronic neuro-inflammation; and together, these
therapies will improve long term survival. The specific aims of this project are to:
Aim 1: Determine the therapeutic effects of intranasal ORXA treatment on early neurophysiological recovery,
cognitive and behavioral outcome following post-CA coma.
Aim 2: Determine the window of anti-inflammatory therapeutic effects of intranasal ORXA applied immediately
post-resuscitation.
Aim 3: Demonstrate that treatment with dendrimer nanotherapy using dendrimer conjugated to N-acetyl-L-
cysteine (D-NAC), increases survival, improves neurobehavior and reduces chronic neuro-inflammation, after
resuscitation.
Aim 4: Achieve early arousal and neuroprotective effect from post-CA neuroinflamation by sequentially using
of intranasal ORXA and D-NAC for sustained neuroprotection leading to improved long term neurological
outcomes and survival post-CA.
There are very limited current therapeutic solutions for improving survival and cognitive outcome after global
ischemia resulting from CA. Our dual approaches, intranasal ORXA delivery and dendrimer mediated targeting,
serve the unmet needs of promoting arousal, and mitigating post-CA neuro-inflammation for patients. Further,
the intranasal delivery approach, once validated, should be amenable to rapid clinical translation. Overall, our
research lays the groundwork for future clinical studies directed at improving the patient outcome after
resuscitation.
摘要
心脏骤停(CA)对生存和脑复苏具有破坏性后果,即使在成功复苏后
伤势可能会相当严重。我们研究的广泛目标是开发可翻译的治疗技术
用于减轻CA后全脑缺血所致的脑损伤。一种流行的解决方案是治疗性低温。
(Th)。虽然TH已被证明可以改善预后,但它并不能促进觉醒或减少神经功能。
发炎。我们现在提出了一种新的潜在的翻译交付方法来促进唤醒
ORXA鼻腔给药。此外,我们还重点考察了其内在的生物分布和抗
树枝状大分子在CA术后慢性长期存活中的炎症特性。我们建议发现者
我们希望展示的实验将导致临床上可翻译的解决方案。
这项建议是建立在令人振奋的初步结果之上的。我们发现了一种将目标对准
食欲素-A(Orxine-A,ORXA)的递送途径。这个想法得到了我们的初步研究的支持
这首先表明,脑室内(ICV)ORXA治疗可以减少炎症,此外,还可以迅速
提高唤醒能力。我们的新型定量脑电(QEEG)监测进一步验证了这一思想
技术我们观察到CA脑损伤后由于神经炎症造成的脑损伤和不良预后。
在我们的初步研究中,我们发现树状大分子,特别是树状大分子-N-乙酰半胱氨酸(D-
NAC),发生在受损的大脑区域。我们已经证明树枝状大分子具有靶向治疗作用。
通过减轻神经炎症、氧化应激和
兴奋性毒性。此外,我们将我们的工作扩展到长期观察,并建立了针对性别的模型。
在拟议的调查中,我们将利用经过广泛研究和验证的CA和
复苏,建议在男性和女性受试者中进行急性和慢性实验,并进行
全身血流监测、电生理(QEEG)监测、综合行为监测
检查和组织病理学分析。
我们的主要假设是,鼻腔内的ORXA将启动大脑唤醒效应和早期抗炎
反应,而树枝状大分子纳米疗法,D-NAC,将减少慢性神经炎症;总的来说,这些
治疗将提高长期存活率。该项目的具体目标是:
目的1:观察鼻腔给药对早期神经生理学恢复的影响。
CA昏迷后的认知和行为结局。
目的2:确定鼻腔即刻应用ORXA的抗炎疗效窗口
复苏后。
目的3:论证N-乙酰-L偶联的树枝状大分子纳米治疗
半胱氨酸(D-NAC),增加存活率,改善神经行为,减少慢性神经炎症,在
复苏。
目的4:在CA术后神经炎性反应的早期唤醒和神经保护作用
鼻腔应用ORXA和D-NAC进行持续神经保护可改善长期神经功能
CA术后的预后和存活率。
目前用来改善存活率和认知结果的治疗方案非常有限
CA引起的缺血。我们的两种方法,鼻腔给药和树枝状大分子介导的靶向,
服务于促进唤醒和减轻CA术后神经炎症的未得到满足的需求。此外,
鼻腔给药方法一旦得到验证,应适用于快速临床翻译。总的来说,我们的
研究为未来的临床研究奠定了基础,旨在改善术后患者的预后
复苏。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A MINIATURE LASER SPECKLE CONTRAST IMAGER FOR MONITORING OF THE NEURO-MODULATORY EFFECT OF TRANSCRANIAL FOCUSED ULTRASOUND STIMULATION.
- DOI:10.1115/dmd2021-1038
- 发表时间:2021-04
- 期刊:
- 影响因子:0
- 作者:Y. Zeng;Molly Acord;T. Kaovasia;P. Miao;Junfeng Sun;J. Senarathna;N. Theodore;N. Thakor;A. Manbachi
- 通讯作者:Y. Zeng;Molly Acord;T. Kaovasia;P. Miao;Junfeng Sun;J. Senarathna;N. Theodore;N. Thakor;A. Manbachi
Systemic dendrimer-drug nanomedicines for long-term treatment of mild-moderate cerebral palsy in a rabbit model.
- DOI:10.1186/s12974-020-01984-1
- 发表时间:2020-10-25
- 期刊:
- 影响因子:9.3
- 作者:Zhang Z;Lin YA;Kim SY;Su L;Liu J;Kannan RM;Kannan S
- 通讯作者:Kannan S
Systemic administration of dendrimer N-acetyl cysteine improves outcomes and survival following cardiac arrest.
- DOI:10.1002/btm2.10259
- 发表时间:2022-01
- 期刊:
- 影响因子:7.4
- 作者:Modi HR;Wang Q;Olmstead SJ;Khoury ES;Sah N;Guo Y;Gharibani P;Sharma R;Kannan RM;Kannan S;Thakor NV
- 通讯作者:Thakor NV
Hyperacute autonomic and cortical function recovery following cardiac arrest resuscitation in a rodent model.
- DOI:10.1002/acn3.51907
- 发表时间:2023-12
- 期刊:
- 影响因子:5.3
- 作者:Guo, Yu;Gharibani, Payam;Agarwal, Prachi;Cho, Sung-Min;Thakor, Nitish V.;Geocadin, Romergryko G.
- 通讯作者:Geocadin, Romergryko G.
Early Thalamocortical Reperfusion Leads to Neurologic Recovery in a Rodent Cardiac Arrest Model.
- DOI:10.1007/s12028-021-01432-9
- 发表时间:2022-08
- 期刊:
- 影响因子:3.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sujatha Kannan其他文献
Sujatha Kannan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sujatha Kannan', 18)}}的其他基金
NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury
NINDS 创造发现:开发用于治疗新生儿脑损伤的树枝状聚合物-N-乙酰半胱氨酸
- 批准号:
9906957 - 财政年份:2018
- 资助金额:
$ 52.31万 - 项目类别:
Translational Technologies for Ameliorating Brain Injury
改善脑损伤的转化技术
- 批准号:
9765382 - 财政年份:2018
- 资助金额:
$ 52.31万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
9263554 - 财政年份:2016
- 资助金额:
$ 52.31万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
10631173 - 财政年份:2016
- 资助金额:
$ 52.31万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
10530903 - 财政年份:2016
- 资助金额:
$ 52.31万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
9923754 - 财政年份:2016
- 资助金额:
$ 52.31万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
9346116 - 财政年份:2016
- 资助金额:
$ 52.31万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 52.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists